<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="50858">Corticosteroids</z:chebi> and lenalidomide decrease red blood cell transfusion dependence in patients with Diamond-Blackfan <z:hpo ids='HP_0001903'>anemia</z:hpo> (<z:chebi fb="28" ids="35299">DBA</z:chebi>) and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), respectively </plain></SENT>
<SENT sid="1" pm="."><plain>We explored the effects of <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> and lenalidomide, individually and in combination, on the differentiation of primary human bone marrow progenitor cells in vitro </plain></SENT>
<SENT sid="2" pm="."><plain>Both agents promote erythropoiesis, increasing the absolute number of erythroid cells produced from <z:mpath ids='MPATH_458'>normal</z:mpath> CD34(+) cells and from CD34(+) cells with the types of ribosome dysfunction found in <z:chebi fb="28" ids="35299">DBA</z:chebi> and del(5q) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>However, the drugs had distinct effects on the production of erythroid progenitor colonies; <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> selectively increased the number of burst-forming units-erythroid (BFU-E), whereas lenalidomide specifically increased colony-forming unit-erythroid (CFU-E) </plain></SENT>
<SENT sid="4" pm="."><plain>Use of the drugs in combination demonstrated that their effects are not redundant </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> and lenalidomide induced distinct gene-expression profiles </plain></SENT>
<SENT sid="6" pm="."><plain>In coculture experiments, we examined the role of the microenvironment in response to both drugs and found that the presence of macrophages, the central cells in erythroblastic islands, accentuated the effects of both agents </plain></SENT>
<SENT sid="7" pm="."><plain>Our findings indicate that <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> and lenalidomide promote different stages of erythropoiesis and support the potential clinical utility of combination therapy for patients with <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> </plain></SENT>
</text></document>